<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="23445">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01978613</url>
  </required_header>
  <id_info>
    <org_study_id>NN9927-4022</org_study_id>
    <secondary_id>2013-000188-10</secondary_id>
    <secondary_id>U1111-1138-4595</secondary_id>
    <nct_id>NCT01978613</nct_id>
  </id_info>
  <brief_title>Investigation on Safety, Tolerability and Pharmacokinetics of Multiple Doses of NNC0113-0987 in an Oral Formulation in Healthy Subjects</brief_title>
  <official_title>Investigation on Safety, Tolerability and Pharmacokinetics of Multiple Doses of NNC0113-0987 in an Oral Formulation in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is conducted in Europe. The aim of the trial is to investigate safety,
      tolerability and pharmacokinetics (the exposure of the trial drug in the body) of multiple
      doses of NNC0113-0987 in an oral formulation in healthy subjects.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number of treatment emergent adverse events recorded</measure>
    <time_frame>From the time of first dosing (day 0) and until completion of the post-treatment follow-up visit (day 83−97)</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of hypoglycaemic episodes</measure>
    <time_frame>From the time of first dosing (day 0) and until completion of the post-treatment follow-up visit (day 83−97)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the NNC0113-0987 plasma concentration time curve</measure>
    <time_frame>During a dosing interval (0-24 hours) at steady state (day 67, day 68 and day 69)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed NNC0113-0987 plasma concentration</measure>
    <time_frame>During a dosing interval (0-24 hours) at steady state (day 67, day 68 and day 69)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Diabetes</condition>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Oral B (DC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Escalation design. Planned end dose level is 5 mg alternative dosing condition (fasting for 30 minutes post-dosing)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Escalation design. Planned end dose level is 20 mg standard dosing condition (fasting for 120 minutes post-dosing)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Escalation design. Planned end dose level is 10 mg standard dosing condition (fasting for 120 minutes post-dosing)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Escalation design. Planned end dose level is 5 mg standard dosing condition (fasting for 120 minutes post-dosing)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Escalation design. Planned end dose level is 2.5 mg standard dosing condition (fasting for 120 minutes post-dosing)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NNC0113-0987</intervention_name>
    <description>Tablets for once-daily oral administration. Multiple doses with sequential dose increments over 10 weeks. The end-dose levels and the dose levels during the escalation regime may be adapted during trial conduct based on safety evaluations.</description>
    <arm_group_label>Oral B (DC)</arm_group_label>
    <arm_group_label>Oral D</arm_group_label>
    <arm_group_label>Oral C</arm_group_label>
    <arm_group_label>Oral B</arm_group_label>
    <arm_group_label>Oral A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Tablets for one-daily oral administration.</description>
    <arm_group_label>Oral B (DC)</arm_group_label>
    <arm_group_label>Oral D</arm_group_label>
    <arm_group_label>Oral C</arm_group_label>
    <arm_group_label>Oral B</arm_group_label>
    <arm_group_label>Oral A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male subject, who is considered to be generally healthy, based on the medical
             history, physical examination, and the results of vital signs, electrocardiogram and
             laboratory safety tests performed during the screening visit, as judged by the
             investigator

          -  Age 18-64 years (both inclusive) at the time of signing informed consent

          -  Body mass index (BMI): 20.0-29.9 kg/m^2 (both inclusive)

        Exclusion Criteria:

          -  History of, or presence of, cancer, diabetes or any clinically significant
             cardiovascular, respiratory, metabolic, renal, hepatic, gastrointestinal,
             endocrinological, haematological,dermatological, venereal, neurological, psychiatric
             diseases or other major disorders, as judged by the investigator

          -  Personal or family history of medullary thyroid carcinoma or multiple endocrine
             neoplasia syndrome type 2

          -  History of chronic pancreatitis or idiopathic acute pancreatitis

          -  Subject with previous gastrointestinal surgery, except subjects that underwent
             uncomplicated surgical procedures such as appendectomy, hernia surgery, biopsies, as
             well as colonic and gastric endoscopy

          -  Use of prescription or non-prescription medicinal products and herbal products
             (except routine vitamins) within three weeks preceding the dosing period. Occasional
             use of paracetamol or acetylsalicylic acid is permitted
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Registry (GCR, 1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <zip>14050</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://novonordisk-trials.com</url>
    <description>Clinical Trials at Novo Nordisk</description>
  </link>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 1, 2014</lastchanged_date>
  <firstreceived_date>November 1, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
